Chemotherapy and/or radiotherapy after surgery for ovarian carcinosarcoma

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Athavale, Ram ^a   Godfrey, K ^b   Deane, K H O ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOSARCOMA; HUMAN; METHODOLOGY; MIXED MULLERIAN TUMOR; OVARY CARCINOSARCOMA; QUALITY CONTROL; REVIEW; TREATMENT OUTCOME;

EID: 42749103977     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006246     Document Type: Review

References (14)

1. Ariyoshi K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 2000;37 (5):427-36.
2. Barnholtz-Sloan JS, Morris R, Malone JM, Jr, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecologic Oncology 2004;93(2):506-12.
3. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstetrics and Gynecology 1995;85(5 Pt 1):735-9.
4. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004;100(10):2148-53.
5. Carlson JA, Edwards C, Wharton JT, Gallager HS, Delclos L, Rutledge F. Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy. Cancer 1983;52 (8):1473-7.
6. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecologic Oncology 2002;85(3):459-63.
7. Hanjani P, Petersen RO, Lipton SE, Nolte SA. Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature. Obstetrics and Gynecological Surveys 1983;38(9):537- 45.
8. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, et al. Carcinosarcoma of the ovary. British Journal of Cancer 2003;88 (5):654-7.
9. Higgins JPT, Green S editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. John Wiley & Son. Ltd, Chichester, UK.
10. Prendiville J, Murphy D, Renninson J, Buckley H, Crowther D. Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital. International Journal of Gynecological Cancer 1994; 4(3):200-5.
11. Russell PB, Solomon HJ. Malignant mullerian and miscellaneous mesenchymal tumors of ovary ('ovarian sarcomas'). In: CopplesonM editor(s). Gynecologic Oncology. 2nd Edition. Churchill Livingstone, 1992:971-86.
12. Simon SR, Wang SE, Uhl M, Shackney S. Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. Gynecologic Oncology 1991;41(2):161-6.
13. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecologic Oncology 2004;93(2):336-9.
14. Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecologic Oncology 1989;32(2):228-32.